PKI-179 (CAS 1197160-28-3)
QUICK LINKS
PKI-179 is a research compound of interest in the field of biochemistry, particularly in the study of protein kinase inhibition. It is used as a tool compound to investigate the intracellular signaling pathways that are regulated by various protein kinases. By inhibiting specific kinase activity, PKI-179 helps scientists to elucidate the role of these enzymes in cellular functions such as growth, proliferation, and differentiation. The compound is also useful in studying the mechanisms of kinase regulation and the effects of kinase dysregulation. In addition, PKI-179 is employed in the screening of kinase targets for potential new research areas, as well as in the assessment of signal transduction processes that are mediated by phosphorylation events. Researchers may further use this compound to explore the cross-talk between different signaling pathways and the potential for combinatorial regulation by multiple kinases.
PKI-179 (CAS 1197160-28-3) References
- Stereoselective synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179. | Chen, Z., et al. 2010. J Org Chem. 75: 1643-51. PMID: 20112997
- PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. | Venkatesan, AM., et al. 2010. Bioorg Med Chem Lett. 20: 5869-73. PMID: 20797855
- Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. | Shuttleworth, SJ., et al. 2011. Curr Med Chem. 18: 2686-714. PMID: 21649578
- Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? | Sabbah, DA., et al. 2011. Curr Med Chem. 18: 5528-44. PMID: 22172063
- Recent developments of small molecule PI3K/mTOR dual inhibitors. | Liu, YN., et al. 2013. Mini Rev Med Chem. 13: 2047-59. PMID: 24195664
- Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring. | Andrs, M., et al. 2015. J Med Chem. 58: 41-71. PMID: 25387153
- A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. | Mohd Rehan,. 2015. J Mol Graph Model. 62: 226-234. PMID: 26500112
- Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. | Zuo, SJ., et al. 2016. Bioorg Med Chem. 24: 179-90. PMID: 26706113
- Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer. | Krieger, KL., et al. 2019. Int J Mol Sci. 20: PMID: 31771139
- Research progress of mTOR inhibitors. | Chen, Y. and Zhou, X. 2020. Eur J Med Chem. 208: 112820. PMID: 32966896
- Chemical and Structural Strategies to Selectively Target mTOR Kinase. | Borsari, C., et al. 2021. ChemMedChem. 16: 2744-2759. PMID: 34114360
- RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. | Fang, L., et al. 2022. Nat Commun. 13: 3181. PMID: 35676246
- Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach. | Abd Emoniem, N., et al. 2023. SAR QSAR Environ Res. 34: 163-182. PMID: 36853097
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PKI-179, 5 mg | sc-364591 | 5 mg | $228.00 |